Stock LLM Wiki

報告_MS_自動化中國7月PMI_20260802

更新 2026-08-04

PDF 原檔:報告_MS_自動化中國7月PMI_20260802_original.pdf

已驗證圖片清單(Step 2.5,2026-08-04 逐張 Read)

檔名 分類 內容(親眼所見)
260803_ms_automation_001.png 裝飾/廣告 MS「Asia Summer School 2026」活動 banner,非資料圖,不得嵌入 lib
260803_ms_automation_002.png 評等沿革圖 亞德客(1590.TW)股價(藍線,約 NT$800-1,500)與 MS 目標價階梯(紅虛線,1,050→…→1,050→2,000),2023/08-2026/08
260803_ms_automation_003.png 評等沿革圖 上銀(2049.TW)股價(藍線,約 NT$180-370)與 MS 目標價階梯(205→…→310→160→400),2023/08-2026/08

原始內容

M August 2, 2026 10:53 PM GMT

Greater China Technology Hardware | Asia Pacific

Automation - Read-across from China's July Manufacturing PMI

In this report, we focus on China's manufacturing PMI, which we see as a potential catalyst for Airtac's and Hiwin's share prices.

China's manufacturing PMI dropped to 49.2 in July from 50.3 in June:

  • This came in lower than both our estimate and consensus of 50.1.
  • The major drag was from the production (-1.5ppt MoM to 49.9) and new orders (-2.7ppt MoM to 48.5), while export was relatively resilient (new export orders (-0.5ppt MoM to 49.6).
  • Our macro team pointed out that there might be room for broader easing this fall, if the July-August growth disappoints, since the government has urged faster execution of the Rmb2tn fiscal impulse in 2H26.

Our view:

  • We think the softer Chroma manufacturing PMI might weigh on the near term sentiment toward the names in the industrial automation space, especially those with high exposure to China, though we will closely monitor whether this develops into a trend in the coming months.
  • In the automation group in Taiwan, we like Airtac and Hiwin as they got their company specific drivers on top of the overall market dynamics:
  • ° Airtac (1590.TW, OW) should continue to benefit from its own share gains and incremental contribution from linear guides. Valuation appears undemanding at 19x 2027e P/E (vs. the 25x average since 2020).
  • ° Hiwin (2049.TW, OW) should show more margin expansion in coming quarters, supported by higher utilization and price hikes. We see potential share price upside at the current 28x 2027e P/E vs. peak cycle valuation of 35-40x.

Update

Morgan Stanley Taiwan Limited+

Derrick Yang

Equity Analyst

Derrick.Yang@morganstanley.com

+886 2 2730-2862

Vivi Huang

Research Associate

Vivi.Huang@morganstanley.com

+886 2 2730-2860

Morgan Stanley Asia Limited+

Andy Meng, CFA

Equity Analyst

Andy.Meng@morganstanley.com

+852 2239-7689

260803_ms_automation_001

Greater China Technology Hardware

Asia Pacific

Industry View

In-Line

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to FINRA restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

M

AlphaSignals Catalyst Event Reaction

Company / Catalyst Date Impact to thesis Catalyst versus expectation
AirTAC International 1590.TW
China July Manufacturing PMI 31 Jul 2026 Unchanged Modest downside surprise
Hiwin Technologies Corp. 2049.TW
China July Manufacturing PMI 31 Jul 2026 Unchanged Modest downside surprise

M

Valuation Methodology and Risks

AirTAC International (1590.TW)

Base case, 29x 2027e P/E. We believe this methodology better captures earnings growth momentum for industrial automation component plays (market sentiment moves along with business cycles). As the industry enters an up-cycle, we think applying a near-peak cycle valuation of 29x P/E is reasonable given the stronger business outlook.

Risks to Upside

  • n Stronger macroeconomic climate in China
  • n Stronger-than-expected demand from industrial automation

Risks to Downside

  • n Sharper economic downturn in China
  • n Miniature linear guideway business development taking more time
  • n Larger-than-expected investment in new products but weaker-than-expected demand

Hiwin Technologies Corp. (2049.TW)

Base case, P/E. We think this valuation methodology better captures Hiwin's earnings growth momentum, as its valuation tends to move with the business cycle. We apply a target multiple of 37x to our 2027 EPS estimate. We view this multiple as justified by the 44% operating profit CAGR we project for 2025-28.

Risks to Upside

  • n Stronger industrial automation demand pickup.
  • n Market share gains.
  • n Earlier-than-expected revenue contribution from humanoids.

Risks to Downside

  • n Weaker industrial automation demand.
  • n More pricing pressure.
  • n Market share loss.
  • n More broad-based impact on the global economy from geopolitical risks.

M

Disclosure Section

The information and opinions in Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the responsibility for its contents) and/or Morgan Stanley Asia (Singapore) Pte. (Registration number 199206298Z) and/or Morgan Stanley Asia (Singapore) Securities Pte Ltd (Registration number 200008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Australia Limited (A.B.N. 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley Wealth Management Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian financial services license No. 240813, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited having Corporate Identification No (CIN) U22990MH1998PTC115305, regulated by the Securities and Exchange Board of India ('SEBI') and holder of licenses as a Research Analyst (SEBI Registration No. INH000001105); Stock Broker (SEBI Stock Broker Registration No. INZ000244438), Merchant Banker (SEBI Registration No. INM000011203), and depository participant with National Securities Depository Limited (SEBI Registration No. IN-DP-NSDL-567-2021) having registered office at Altimus, Level 39 & 40, Pandurang Budhkar Marg, Worli, Mumbai 400018, India; Telephone no. +91-22-61181000; Compliance Officer Details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: tejarshi.hardas@morganstanley.com; Grievance officer details: Mr. Tejarshi Hardas, Tel. No.: +91-22-61181000 or Email: msic-compliance@morganstanley.com which accepts the responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research, and their affiliates (collectively, "Morgan Stanley"). Morgan Stanley India Company Private Limited (MSICPL) may use AI tools in providing research services. All recommendations contained herein are made by the duly qualified research analysts.

For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/eqr/disclosures/webapp/generalresearch, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA.

For valuation methodology and risks associated with any recommendation, rating or price target referenced in this research report, please contact the Client Support Team as follows: US/Canada +1 800 303-2495; Hong Kong +852 2848-5999; Latin America +1 718 754-5444 (U.S.); London +44 (0)20-7425-8169; Singapore +65 6834-6860; Sydney +61 (0)2-9770-1505; Tokyo +81 (0)3-6836-9000. Alternatively you may contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY 10036 USA.